Senores
Committed to Global Wellness!

SENORES PHARMACEUTICALS LIMITED

Strong Financial & Operational Performance for Q1 FY27

Ahmedabad, Gujarat, 27th July 2026 – Senores Pharmaceuticals Limited, a global research driven pharmaceutical company engaged in developing and manufacturing specialty, niche and complex products for Regulated and Emerging Markets, announced its unaudited Financial Result for the quarter ended 30th June 2026.

Q1 FY27 CONSOLIDATED FINANCIAL HIGHLIGHTS

Revenue	EBITDA	PAT
₹ 180 crs	₹ 54 crs	₹ 31 crs
+36% *Y-o-Y*	+87% *Y-o-Y*	+56% *Y-o-Y*

Q1 FY27 SEGMENTAL HIGHLIGHTS

Segment Revenue (₹ crs)	Q1FY27	Q1FY26	*Y-o-Y*
Regulated Markets	127.8	90.1	*41.9%*
Emerging Markets	37.6	29.0	*29.6%*
Branded Generics	8.0	8.2	*-2.4%*
Others	6.8	5.2	*29.2%*
Total Revenue	**180.2**	**132.6**	***35.9%***

Senores
Committed to Global Wellness!

Q1 FY27 FINANCIAL & BUSINESS HIGHLIGHTS

✓ Consistently strong and broad based growth across businesses

- Consistently delivering robust performance with Revenue for Q1FY27 growing **by 36% Y-o-Y.**
- Strong revenue growth delivered in Regulated & Emerging markets with revenue growth of **42% & 30% respectively** on a Y-o-Y basis.

✓ Robust improvement in profitability

- EBIDTA for Q1FY27 grew by 87% with margin expansion of ~800 bps on a Y-o-Y basis.
- Steady focus on manufacturing & cost efficiency enabling sustainable margin growth & expansion

✓ Continued expansion of product portfolio

- Nearly doubled our Regulated Markets portfolio, expanding from 30 ANDAs as of June 2025 to 58 approved ANDAs as of June 2026, out of which 23 ANDAs have been commercialized.

✓ Emerging Markets on Steady Trajectory

- Emerging Markets business on a steady growth trajectory. Revenue growing by ~30% Y-o-Y in Q1 FY27. EBITDA Margin stood at approximately 14%, Supported by an increasing focus on niche products and streamlined go-to-market strategies.

✓ Outlook remains extremely positive

- With a strong foundation, differentiated product portfolio, and a clearly defined roadmap, we are well positioned to sustain our growth momentum and deliver another year of strong performance in FY27 and beyond.
- Based on the current business outlook and execution visibility, we expect strong revenue growth & expanding profitability for FY27. This confidence is underpinned by a robust product pipeline, with strong visibility of commercial launches over the coming quarters.

Senores
Committed to Global Wellness!

Commenting on the performance, ***Mr. Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited*** *said,*

"Building on the strong momentum from the previous year and driven by our well-defined strategic priorities, we delivered a healthy performance in the first quarter of FY27 despite a challenging operating environment.

Our Regulated Markets business delivered strong performance in Q1FY27, registering a robust 42% year-over-year revenue growth. This was driven by the continuous expansion of our product portfolio and differentiated sales & distribution channels. Through a balanced blend of in-house development and targeted acquisitions, we have strategically strengthened our ANDA portfolio.

The Emerging Markets business is on a steady trajectory as well. With the shift towards niche products, we are now near mid teens EBITDA Margin. Importantly, the Emerging Markets business is now cash flow positive.

The addition of Baroda-based USFDA approved manufacturing plant enhances scalability, deepens access to Regulated Markets, enables accelerated product launches, improves operating leverage, margins, and expands CDMO & CMO opportunities, positioning Senores for sustained growth. Production is already ramped up at Apnar facility, with full scale-up and further expansion is expected over the next 12–18 months.

Our specific purpose marketing and distribution subsidiaries are expected to scale up significantly over the next few years and will structurally advance our entire U.S. business to multifold.

All in all, we have continued to deliver on our stated commitments through disciplined execution, operational excellence, and a relentless focus on growth. Our ability to consistently execute across functions while maintaining financial discipline reflects the resilience of our business model, the credibility of our long-term strategy, and the execution-driven culture that is deeply embedded across Senores. We remain confident in sustaining this momentum in the years ahead, led by robust product pipeline, expanded manufacturing capacities, and a strengthened R&D infrastructure."

About Senores Pharmaceuticals Limited:

Senores Pharmaceuticals Limited is a global research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.

The companies' current portfolio includes 58 ANDAs and 16 CMO/CDMO commercial products that are permitted for distribution in the USA. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets catering to more than 40 countries. The company has currently approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with 513 product registrations and 942 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (API).

Senores has 3 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA/BAA compliant, second in Gujarat, which is also US-FDA approved and the third in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to Emerging Markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India).

Safe Harbour Statement:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results changed assumptions or other factors.

For more information, please contact

Company : SENORES PHARMACEUTICALS LIMITED

CIN: L24290GJ2017PLC100263

Mr. Deval Shah – Whole Time Director & CFO

Email: investors@senorespharma.com

For updates and specific queries, please visit www.senorespharma.com

Investor Relations : Strategic Growth Advisors

CIN: U74140MH2010PTC204285

www.sgapl.net

Mr. Sagar Shroff – sagar.shroff@sgapl.net / +91 98205 19303

Mr. Tanay Shah – tanay.shah@sgapl.net / +91 98333 91899